CDK4/6 inhibitor-mediatated radiosensitization of estrogen receptor positive breast cancer

被引：0
|
作者：
Pesch, Andrea M. [1 ]
Hirsh, Nicole [1 ]
Chandler, Benjamin C. [1 ]
Michmerhuizen, Anna R. [1 ]
Ritter, Cassandra L. [1 ]
Androsiglio, Marlie [1 ]
Wilder-Romans, Kari [1 ]
Liu, Meilan [1 ]
Gersch, Christina L. [1 ]
Larios, Jose M. [1 ]
Rae, James M. [1 ]
Speers, Corey W. [1 ]
机构：
[1] Univ Michigan, Ann Arbor, MI 48109 USA
来源：
CANCER RESEARCH | 2020年 / 80卷 / 16期
关键词：
D O I：
10.1158/1538-7445.AM2020-6280
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
6280
引用
收藏
页数：2
相关论文
共 50 条
  • [41] Pfizer's CDK4/6 inhibitor approved for advanced breast cancer
    Chris Morrison
    Nature Biotechnology, 2015, 33 : 323 - 324
  • [42] Combination of androgen receptor inhibitor enzalutamide with the CDK4/6 inhibitor ribociclib in triple negative breast cancer cells
    Choupani, Edris
    Madjd, Zahra
    Saraygord-Afshari, Neda
    Kiani, Jafar
    Hosseini, Arshad
    PLOS ONE, 2022, 17 (12):
  • [43] The Ongoing Search for Biomarkers of CDK4/6 Inhibitor Responsiveness in Breast Cancer
    Schoninger, Scott F.
    Blain, Stacy W.
    MOLECULAR CANCER THERAPEUTICS, 2020, 19 (01) : 3 - 12
  • [44] CDK4/6 inhibitors in HR-positive breast cancer immunotherapy
    Shen, Mimi
    Ma, Zhiyuan
    Zhu, Jiaxing
    Wen, Guorong
    Jin, Hai
    An, Jiaxing
    Tuo, Biguang
    Liu, Xuemei
    Li, Taolang
    BIOORGANIC CHEMISTRY, 2025, 154
  • [45] CDK4/6 inhibitors in HER2-positive breast cancer
    Corona, Silvia Paola
    Ravelli, Andrea
    Cretella, Daniele
    Cappelletti, Maria Rosa
    Zanotti, Laura
    Dester, Martina
    Gobbi, Angela
    Petronini, Pier Giorgio
    Generali, Daniele
    CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY, 2017, 112 : 208 - 214
  • [46] Dual Targeting of CDK4/6 and BCL2 Pathways Augments Tumor Response in Estrogen Receptor-Positive Breast Cancer
    Whittle, James R.
    Vaillant, Francois
    Surgenor, Elliot
    Policheni, Antonia N.
    Giner, Goknur
    Capaldo, Bianca D.
    Chen, Huei-Rong
    Liu, He K.
    Dekkers, Johanna F.
    Sachs, Norman
    Clevers, Hans
    Fellowes, Andrew
    Green, Thomas
    Xu, Huiling
    Fox, Stephen B.
    Herold, Marco J.
    Smyth, Gordon K.
    Gray, Daniel H. D.
    Visvader, Jane E.
    Lindeman, Geoffrey J.
    CLINICAL CANCER RESEARCH, 2020, 26 (15) : 4120 - 4134
  • [47] CDK4/6 inhibitor palbociclib enhances the effect of pyrotinib in HER2-positive breast cancer
    Zhang, Kai
    Hong, Ruoxi
    Kaping, Lee
    Xu, Fei
    Xia, Wen
    Qin, Ge
    Zheng, Qiufan
    Lu, Qianyi
    Zhai, Qinglian
    Shi, Yanxia
    Yuan, Zhongyu
    Deng, Wuguo
    Chen, Miao
    Wang, Shusen
    CANCER LETTERS, 2019, 447 : 130 - 140
  • [48] Mdm2 inhibition synergises with endocrine therapy or cdk4/6 inhibition for the treatment of estrogen receptor-positive breast cancer
    Portman, Neil
    Milioli, Heloisa
    Alexandrou, Sarah
    Coulson, Rhiannon
    Yong, Aliza
    Fernandez, Kristine
    Chia, KeeMing
    Halilovic, Ensar
    Segara, Davendra
    Parker, Andrew
    Haupt, Sue
    Haupt, Ygal
    Tilley, Wayne
    Swarbrick, Alex
    Caldon, Liz
    Lim, Elgene
    CANCER RESEARCH, 2021, 81 (04)
  • [49] Metabolic alterations in Estrogen Receptorpositive breast cancer contributing to CDK4/6 resistance
    Allam, Mayar
    Coskun, Ahmet
    Hu, Thomas
    Gu, Yuan
    Badve, Sunil
    Gokmen-Polar, Yesim
    CANCER RESEARCH, 2024, 84 (09)
  • [50] Mechanisms of sensitivity and resistance to CDK4/CDK6 inhibitors in hormone receptor-positive breast cancer treatment
    Glaviano, Antonino
    Wander, Seth A.
    Baird, Richard D.
    Yap, Kenneth C. -H.
    Lam, Hiu Yan
    Toi, Masakazu
    Carbone, Daniela
    Geoerger, Birgit
    Serra, Violeta
    Jones, Robert H.
    Ngeow, Joanne
    Toska, Eneda
    Stebbing, Justin
    Crasta, Karen
    Finn, Richard S.
    Diana, Patrizia
    Vuina, Karla
    de Bruin, Robertus A. M.
    Surana, Uttam
    Bardia, Aditya
    Kumar, Alan Prem
    DRUG RESISTANCE UPDATES, 2024, 76
12345